|
94 Companies |
|
165 Products |
|
165 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
1453 News |
|
| «12345678910111213...2930» |
- ||||| Praluent (alirocumab) / Sanofi, Regeneron
Enrollment closed: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan (clinicaltrials.gov) - Oct 26, 2015
P3, N=184, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting
- || Trial primary completion date: The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=214, Recruiting, Sponsor: Unilever R&D
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2015 --> Dec 2016
- || Fabrazyme (agalsidase beta) / Sanofi
Trial completion: FIELD: A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-na (clinicaltrials.gov) - Oct 19, 2015
P3b, N=31, Completed, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Oct 2015 --> Dec 2016 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: The Effect of a Scratch Off Prompt on Health Engagement (clinicaltrials.gov) - Oct 14, 2015
P=N/A, N=84953, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Not yet recruiting --> Completed | N=15000 --> 84953 | Initiation date: Jul 2011 --> Jul 2014 | Trial primary completion date: Jan 2012 --> Oct 2014
- Enrollment closed, Trial primary completion date: A Mediterranean-style Breakfast and Postprandial Lipid Disorders in Obese Pre-adolescents and Adults (clinicaltrials.gov) - Oct 8, 2015
P=N/A, N=48, Active, not recruiting, Sponsor: National Research Council, Spain
Not yet recruiting --> Completed | N=15000 --> 84953 | Initiation date: Jul 2011 --> Jul 2014 | Trial primary completion date: Jan 2012 --> Oct 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2012 --> Dec 2015
- Enrollment change, Trial primary completion date, HEOR: U of A/ U of M Beans and Peas Health Claim Project (clinicaltrials.gov) - Oct 7, 2015
P1/2, N=180, Recruiting, Sponsor: University of Alberta
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2012 --> Dec 2015 N=150 --> 180 | Trial primary completion date: Apr 2015 --> Dec 2015
- Trial completion: LeSIP: Lean Seafood Intake and Postprandial Metabolism (clinicaltrials.gov) - Oct 6, 2015
P=N/A, N=27, Completed, Sponsor: National Institute of Nutrition and Seafood Research, Norway
N=150 --> 180 | Trial primary completion date: Apr 2015 --> Dec 2015 Active, not recruiting --> Completed
- ||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial initiation date: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan (clinicaltrials.gov) - Oct 5, 2015
P3, N=184, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Initiation date: Oct 2014 --> Jan 2015
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed, Trial primary completion date: SPIRE-SI: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (clinicaltrials.gov) - Oct 3, 2015
P3, N=150, Active, not recruiting, Sponsor: Pfizer
Initiation date: Oct 2014 --> Jan 2015 Trial primary completion date: Feb 2015 --> Nov 2015 | Recruiting --> Active, not recruiting
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed: SPIRE-LL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (clinicaltrials.gov) - Oct 3, 2015
P3, N=690, Active, not recruiting, Sponsor: Pfizer
Trial primary completion date: Feb 2015 --> Nov 2015 | Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed: SPIRE-LDL: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (clinicaltrials.gov) - Oct 3, 2015
P3, N=1932, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| bococizumab (RN316) / Pfizer
Enrollment closed: SPIRE-FH: A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Oct 2, 2015
P3, N=300, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Repatha (evolocumab) / Amgen, Astellas
Enrollment closed, Enrollment change: EBBINGHAUS: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (clinicaltrials.gov) - Sep 28, 2015
P3, N=1972, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=4000 --> 1972
- ||||| evacetrapib (LY2484595) / Eli Lilly
Enrollment closed, Combination therapy: A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia (clinicaltrials.gov) - Sep 28, 2015
P3, N=147, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=4000 --> 1972 Recruiting --> Active, not recruiting
- |||| Trial completion, Enrollment change: Telephone Based Management of Hyperlipidemia (clinicaltrials.gov) - Sep 26, 2015
P4, N=70, Completed, Sponsor: Temple University
Recruiting --> Active, not recruiting Recruiting --> Completed | N=100 --> 70
- || Enrollment closed, Trial primary completion date: VASALA: Alpha-linolenic Acid and Blood Pressure (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=72, Active, not recruiting, Sponsor: Maastricht University Medical Center
Recruiting --> Completed | N=100 --> 70 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Oct 2015
- |||| atorvastatin / Generic mfg., fenofibrate/pravastatin / Generic mfg.
Trial primary completion date, Monotherapy, Head-to-Head: Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin (clinicaltrials.gov) - Sep 25, 2015
P3, N=366, Recruiting, Sponsor: Yooyoung Pharmaceutical Co.,Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Oct 2015 Trial primary completion date: Jul 2015 --> May 2016
- Trial primary completion date: Outer Thigh Study With Varied Treatment Parameters (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Zeltiq Aesthetics
Trial primary completion date: Jul 2015 --> May 2016 Trial primary completion date: Jun 2015 --> Nov 2015
- Biomarker, Trial primary completion date: Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=122, Recruiting, Sponsor: National Institute of Nursing Research (NINR)
Trial primary completion date: Jun 2015 --> Nov 2015 Trial primary completion date: Dec 2017 --> Jul 2017
- ||||||| atorvastatin immediate-release/losartan potassium delayed release (HL 040) / Yuhan Corp, Yuhan Corp, Daewoong Pharma
Trial completion: Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia (clinicaltrials.gov) - Sep 25, 2015
P3, N=356, Completed, Sponsor: HanAll BioPharma Co., Ltd.
Trial primary completion date: Dec 2017 --> Jul 2017 Recruiting --> Completed
- Trial primary completion date: Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent. (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=60, Active, not recruiting, Sponsor: McGill University Health Center
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Oct 2015
- ||||||| Praluent (alirocumab) / Sanofi, Regeneron
Trial completion: Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) (clinicaltrials.gov) - Sep 24, 2015
P3, N=217, Completed, Sponsor: Sanofi
Trial primary completion date: Jun 2015 --> Oct 2015 Active, not recruiting --> Completed
- ||||||| Rosuzet (rosuvastatin/ezetimibe) / Hanmi, Merck (MSD)
Trial completion: Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia (clinicaltrials.gov) - Sep 22, 2015
P3, N=412, Completed, Sponsor: Hanmi Pharmaceutical Company Limited
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Trial completion: A Trial to Evaluate the Efficacy of AB-Life Probiotic Product on LDL-Cholesterol Reduction in Moderate Hypercholesterolemia (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=104, Completed, Sponsor: AB Biotics, SA
Recruiting --> Completed Recruiting --> Completed
- ||||| ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
Enrollment closed, Trial primary completion date, Combination therapy: Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE) (clinicaltrials.gov) - Sep 15, 2015
P3, N=290, Active, not recruiting, Sponsor: LG Life Sciences
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- |||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
Trial completion, Trial primary completion date: Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension (clinicaltrials.gov) - Sep 14, 2015
P2, N=143, Completed, Sponsor: Esperion Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jul 2015
- | rocacetrapib (CKD-519) / Chong Kun Dang
Trial completion: Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 (clinicaltrials.gov) - Sep 14, 2015
P1, N=41, Completed, Sponsor: Chong Kun Dang Pharmaceutical
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jul 2015 Not yet recruiting --> Completed
- |||| Nexletol (bempedoic acid) / Esperion Therap, Otsuka, Daiichi Sankyo
Trial completion: Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy (clinicaltrials.gov) - Sep 14, 2015
P2, N=133, Completed, Sponsor: Esperion Therapeutics
Not yet recruiting --> Completed Recruiting --> Completed
- Trial withdrawal: Genomic Dissection of a QTL Affecting the Lipid Profile (clinicaltrials.gov) - Sep 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: Medical College of Wisconsin
Recruiting --> Completed Completed --> Withdrawn
- || BioAstin (astaxanthin) / Cyanotech
Enrollment closed, Trial primary completion date: LLAX: Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia (clinicaltrials.gov) - Sep 9, 2015
P=N/A, N=68, Active, not recruiting, Sponsor: Ajinomoto Foods Europe SAS
Completed --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2015
- ||| Trial completion: LINET: Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter (clinicaltrials.gov) - Sep 4, 2015
P=N/A, N=108, Completed, Sponsor: Fresenius Medical Care Deutschland GmbH
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Sep 2015 Active, not recruiting --> Completed
- Kynamro (mipomersen) / Kastle Therap
Trial completion: MICA: Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis (clinicaltrials.gov) - Sep 3, 2015
P3, N=17, Completed, Sponsor: Ludwig-Maximilians - University of Munich
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Egrifta (tesamorelin acetate) / Theratechnologies, Massachusetts General Hospital
Trial suspension, Trial primary completion date: Egrifta Replacement and Sleep Disordered Breathing (clinicaltrials.gov) - Sep 2, 2015
P=N/A, N=20, Suspended, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Not yet recruiting --> Suspended | Trial primary completion date: Jan 2014 --> Jan 2020
- Trial completion, Enrollment change: One-Day Acceptance and Commitment Training Intervention in Primary Care Patients (clinicaltrials.gov) - Aug 28, 2015
P=N/A, N=44, Completed, Sponsor: University of Iowa
Not yet recruiting --> Suspended | Trial primary completion date: Jan 2014 --> Jan 2020 Active, not recruiting --> Completed | N=150 --> 44
- || nicotinic acid analog (ARI-3037MO) / Arisaph
Trial primary completion date: Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia (clinicaltrials.gov) - Aug 26, 2015
P2, N=80, Recruiting, Sponsor: Arisaph Pharmaceuticals Inc
Active, not recruiting --> Completed | N=150 --> 44 Trial primary completion date: Dec 2015 --> Jun 2016
- Trial completion, Trial primary completion date: RRR: Reducing Risk of Recurrence (clinicaltrials.gov) - Aug 24, 2015
P=N/A, N=150, Completed, Sponsor: Department of Veterans Affairs
Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015
- ||||| Praluent (alirocumab) / Sanofi, Regeneron
Enrollment closed, Trial primary completion date: ODYSSEY OLE: Open Label Study of Long Term Safety Evaluation of Alirocumab (clinicaltrials.gov) - Aug 24, 2015
P3, N=1000, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017
- Trial primary completion date: Soda and Milk Study (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=30, Recruiting, Sponsor: Children's Hospital & Research Center Oakland
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Jul 2015 --> Jul 2016
- Trial primary completion date: Effect of Different Types of Carbohydrates Consumed After Exercise on Blood Fat Levels (clinicaltrials.gov) - Aug 22, 2015
P=N/A, N=25, Active, not recruiting, Sponsor: University of Saskatchewan
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Feb 2015 --> Aug 2015
- |||| Praluent (alirocumab) / Sanofi, Regeneron
Trial primary completion date: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan (clinicaltrials.gov) - Aug 21, 2015
P3, N=184, Recruiting, Sponsor: Sanofi
Trial primary completion date: Feb 2015 --> Aug 2015 Trial primary completion date: Aug 2016 --> Mar 2016
- Trial primary completion date, Adherence: Genetically Guided Statin Therapy (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=375, Recruiting, Sponsor: Duke University
Trial primary completion date: Aug 2016 --> Mar 2016 Trial primary completion date: Nov 2015 --> Apr 2016
- Trial completion: Effects of a Probiotics on the Health of Normal Young Males (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=14, Completed, Sponsor: Centre Hospitalier Universitaire Vaudois
Trial primary completion date: Nov 2015 --> Apr 2016 Recruiting --> Completed
- Biomarker, Trial primary completion date: Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=200, Recruiting, Sponsor: George Washington University
Recruiting --> Completed Trial primary completion date: Jun 2015 --> Nov 2015
- Tredaptive (niacin controlled release/laropiprant) / Merck (MSD)
Trial primary completion date: Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease (clinicaltrials.gov) - Aug 19, 2015
P4, N=32, Terminated, Sponsor: Daniel A. Siniawski
Trial primary completion date: Jun 2015 --> Nov 2015 Trial primary completion date: Apr 2013 --> Jan 2013
- Trial completion, Enrollment change: Dislip-EM: Effectiveness of Motivational Interview in Patients With Dyslipidemia (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=207, Completed, Sponsor: Hospital Universitario Reina Sofia
Trial primary completion date: Apr 2013 --> Jan 2013 Recruiting --> Completed | N=400 --> 207
- | Trial completion: Veterans Walk for Health Study (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=254, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed | N=400 --> 207 Active, not recruiting --> Completed
- Trial completion, Enrollment change: The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults (clinicaltrials.gov) - Aug 17, 2015
P=N/A, N=19, Completed, Sponsor: Purdue University
Active, not recruiting --> Completed Recruiting --> Completed | N=30 --> 19
- Trial completion: MWV_CAPS: Cholesterol Medication Packaging Study (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=245, Completed, Sponsor: Durham VA Medical Center
Recruiting --> Completed | N=30 --> 19 Enrolling by invitation --> Completed
- ||||| Galafold (migalastat) / Amicus
Enrollment closed, Monotherapy: Open-Label Phase 3 Long-Term Safety Study of Migalastat (clinicaltrials.gov) - Aug 12, 2015
P3, N=100, Active, not recruiting, Sponsor: Amicus Therapeutics
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, HEOR: Using Nudges to Implement Comparative Effectiveness (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=19, Completed, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=40 --> 19